CAR T细胞毒性:从床旁到实验室,新型毒性如何启发实验室检查
美国血液学会新兴基因与细胞治疗小组委员会在年会举办首届CAR T细胞毒性科学研讨会,汇总B细胞成熟抗原CAR T细胞后运动障碍、凝血异常和持续性血细胞减少等新兴毒性,探讨肠道菌群与系统性免疫失调等机制,并指出细胞因子检测等临床检验可及性不足,共识呼吁建立登记库以收录新兴毒性和真实世界管理。
要点
- 研讨会汇总了BCMA CAR T细胞后运动障碍、凝血异常和持续性血细胞减少等新兴毒性。
- 系统性免疫失调可能是新兴毒性的核心机制,需研究肿瘤、CAR T细胞与菌群的联系。
- 与会者共识认为亟需建立登记库以收录新兴CAR T细胞毒性及真实世界管理。
核心结论
- 尽管临床表现可能先于病理生理机制被认识,仍需研究这些表现以助发现和预防此类毒性。
- 系统性免疫失调似乎是这些新兴毒性的核心,需研究阐明肿瘤、CAR T细胞与菌群之间的联系。
- 与会者共识认为亟需建立登记库以收录新兴CAR T细胞毒性和真实世界管理。
研究设计与样本
- 美国血液学会新兴基因与细胞治疗小组委员会在年会期间组织了首届CAR T细胞毒性科学研讨会。
- 研讨会旨在汇总CAR T细胞新兴毒性报告、传播床旁到实验室的机制研究并指出临床检验可及性缺口。
主要发现
- 研讨会汇总的CAR T细胞新兴毒性包括B细胞成熟抗原CAR T细胞后运动障碍、凝血异常和持续性血细胞减少。
- 研讨会传播了阐明CAR T细胞毒性病理生理机制的床旁到实验室工作,包括肠道菌群和系统性免疫失调。
- 研讨会指出了细胞因子检测等临床检验可及性的缺口,这些检测可用于扩展毒性监测知识。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple chimeric antigen receptor (CAR) T-cell therapies are US Food and Drug Administration-approved, and several are under development. Although effective for some cancers, toxicities remain a limitation. The most common toxicities, that is, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, are well described. With increasing utilization, providers worldwide are reporting other emergent and often complicated toxicities. Given the evolving toxicity profiles and urgent need to catalog these emerging and emergent CAR T-cell toxicities and describe management approaches, the American Society of Hematology Subcommittee on Emerging Gene and Cell Therapies organized the first scientific workshop on CAR T-cell toxicities during the annual society meeting. The workshop functioned to (1) aggregate reports of CAR T-cell emergent toxicities, including movement disorders after B-cell maturation antigen CAR T cell, coagulation abnormalities, and prolonged cytopenia; (2) disseminate bedside-to-bench efforts elucidating pathophysiological mechanisms of CAR T-cell toxicities, including the intestinal microbiota and systemic immune dysregulation; and (3) highlight gaps in the availability of clinical tests, such as cytokine measurements, which could be used to expand our knowledge around the monitoring of toxicities. Key themes emerged. First, although clinical manifestations may develop before the pathophysiologic mechanisms are understood, they must be studied to aid in the detection and prevention of such toxicities. Second, systemic immune dysregulation appears to be central to these emergent toxicities, and research is needed to elucidate the links between tumors, CAR T cells, and microbiota. Finally, there was a consensus around the urgency to create a repository to capture emergent CAR T-cell toxicities and the real-world management.
引用
- Perna F, Parekh S, Diorio C, et al. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Blood Adv. 2024. PMID: 38861351. doi:10.1182/bloodadvances.2024013044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。